Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Disopyramide
Drug ID BADD_D00693
Description A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
Indications and Usage For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias. It is a Class Ia antiarrhythmic drug.
Marketing Status approved
ATC Code C01BA03
DrugBank ID DB00280
KEGG ID D00303
MeSH ID D004206
PubChem ID 3114
TTD Drug ID D0M4YC
NDC Product Code Not Available
UNII GFO928U8MQ
Synonyms Disopyramide | Diisopyramide | Disopyramide Phosphate | Disopyramide Phosphate (1:1) | Disopyramide Phosphate (1:1), (+-)-Isomer | Disopyramide Phosphate (1:1), (R)-Isomer | Disopyramide Phosphate (1:1), (S)-Isomer | Disopyramide, (+-)-Isomer | Disopyramide, (R)-Isomer | Disopyramide, (S)-Isomer | Disopyramide, D-Tartrate (1:1), (S)-Isomer | Disopyramide, L-Tartrate (1:1), (R)-Isomer | Disopyramide, L-Tartrate (1:1), (S)-Isomer | Disopyramide, L-Tartrate (1:2), (+-)-Isomer | Disopyramide, L-Tartrate, (S)-isomer | Norpace | Palpitin | Palpitine | Rhythmodan | Ritmilen | Rythmilen | SC-13957 | SC 13957 | SC13957 | Disopyramide Monohydrochloride
Chemical Information
Molecular Formula C21H29N3O
CAS Registry Number 3737-09-5
SMILES CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.004204%
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Tension19.06.02.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Torsade de pointes02.03.04.005--Not Available
Urinary hesitation20.02.02.009--Not Available
Urinary retention20.02.02.0110.001911%
Urticaria23.04.02.001; 10.01.06.001--
Ventricular extrasystoles02.03.04.0070.004204%Not Available
Ventricular fibrillation02.03.04.008--
Ventricular tachycardia02.03.04.010--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Hepatic enzyme increased13.03.04.028--Not Available
Cardiac disorder02.11.01.0030.004204%Not Available
Poisoning12.03.01.004--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction19.08.04.001; 21.03.01.007--
Ill-defined disorder08.01.03.049--Not Available
Cardiac fibrillation02.03.02.021--Not Available
Psychotic disorder19.03.01.002--
Small fibre neuropathy17.09.03.021; 14.07.04.007; 05.07.04.0070.001911%Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.0380.004204%Not Available
Therapeutic product effect incomplete08.06.01.0520.007452%Not Available
The 4th Page    First    Pre   4    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene